Filing Details

Accession Number:
0001209191-21-050228
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-06 18:19:30
Reporting Period:
2021-08-04
Accepted Time:
2021-08-06 18:19:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1652130 Intellia Therapeutics Inc. NTLA In Vitro & In Vivo Diagnostic Substances (2835) 364785571
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1777421 Laura Sepp-Lorenzino C/O Intellia Therapeutics, Inc.
40 Erie Street; Suite 130
Cambridge MA 02139
Evp, Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-04 26,000 $13.40 28,391 No 4 M Direct
Common Stock Disposition 2021-08-04 1,471 $135.47 26,920 No 4 S Direct
Common Stock Disposition 2021-08-04 6,814 $136.79 20,106 No 4 S Direct
Common Stock Disposition 2021-08-04 6,344 $137.72 13,762 No 4 S Direct
Common Stock Disposition 2021-08-04 4,419 $138.78 9,343 No 4 S Direct
Common Stock Disposition 2021-08-04 2,772 $139.85 6,571 No 4 S Direct
Common Stock Disposition 2021-08-04 4,054 $140.73 2,517 No 4 S Direct
Common Stock Disposition 2021-08-04 126 $141.63 2,391 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-08-04 26,000 $0.00 26,000 $13.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
109,000 2030-03-01 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.18 to $135.885, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.25 to $137.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.255 to $138.25, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.31 to $139.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.395 to $140.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.395 to $141.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price.
  8. Includes shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan as follows: 760 shares on December 31, 2019; 847 shares on June 30, 2020; 561 shares on December 31, 2020 and 223 shares on June 30, 2021.
  9. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 4, 2021.